Applications of Humanized Mice in the Evaluation of Antibody-Drug Conjugates to Treat Autoimmune Diseases

Join experts from GemPharmatech and BioRay Pharmaceutical as they discuss the use of humanized mice to evaluate antibody-drug conjugates for treating autoimmune diseases.

There are currently thirteen FDA-approved Antibody-Drug Conjugates (ADCs) for cancer treatment, and this promising technology is now showing potential in treating autoimmune diseases in humans. However, due to poor cross-species reactivity between therapeutic antibodies and their targets, uncovering the potential of these therapeutics has proven complicated when using conventional mouse models.

In this webinar, Director of Scientific Engagement at GemPharmatech, Dr. Jun Wang, and President of BioRay Pharmaceutical, Dr. Gang Chen, discuss how humanized mice help overcome the limitations of conventional mouse models and provide insights on how to use these models to evaluate the therapeutic potential of ADCs.

Key Topics Include:

Advantages of using humanized mouse models to evaluate ADCs
Applications of humanized mice to evaluate ADCs in autoimmune disease models
The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADC^TM)

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.

Presenters

Jun Wang, PhD

Director of Scientific Engagement
GemPharmatech

Dr. Jun Wang has over 15 years of experience in biomedical research. Prior to joining GemPharmatech, he served as an Associate Director of Research at Explora Biolabs/Charles River. He has extensive experience with genetically engineered mouse models for drug discovery in various therapeutic areas. Dr. Wang holds a Ph.D. in Developmental Neurobiology from the City of Hope and received his postdoctoral training in pediatric brain cancer research from the Sanford Burnham Prebys Medical Discovery Institute.

Gang Chen, PhD

President
Bioray Pharmaceutical

Dr. Gang Chen is the head of Bioray Pharmaceutical and leads a team of scientists developing novel ADCs for cancer and autoimmune diseases. He has over 25 years of experience in the field of antibody engineering and ADC development. Dr. Chen holds a Ph.D. in Biochemistry from the University of Texas at Austin.

Production Partner

GemPharmatech

GemPharmatech is a global contract research organization that provides genetically engineered mouse models and preclinical research services to the scientific community. We have an extensive library of over 25,000 models including KO/cKO mice, humanized mice, immunodeficient mice, and germ-free mice, and continually expand our library to assist our customers in achieving their research goals. To further support our customers, we also offer custom model generation, breeding, and compound efficacy testing in our offices across China and the United States.

VIEW PROFILE

Additional Content From Scientist.com

How to Avoid Expensive Redesign Cycles in Antibody Discovery

Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.